JPMorgan analyst Tessa Romero initiated coverage of Biohaven with an Overweight rating and $23 price target. The analyst sees the company’s lead asset, BHV-7000, designed to selectively open voltage-gated potassium ion channels expressed in the central nervous system, as well positioned in a "highly valued neurological target." Key opinion leader feedback continues to suggest that there is a high unmet need in patients who are afflicted with treatment-refractory focal seizures and need more efficacious options that are well-tolerated, Romero tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BHVN:
- Biohaven treatment of spinal muscular atrophy granted orphan designation
- Cowen says full sale of BioCryst ‘potentially now even more likely’
- Biohaven initiated with a Buy at BTIG
- George Soros Pulls the Trigger on These 2 “Strong Buy” Stocks
- Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
